Nanotechnology advances in brain tumours: the state of the art

Gloria Invernici, Daniela Tavian, Chiara Redaelli

Research output: Contribution to journalArticlepeer-review

25 Citations (Scopus)

Abstract

Abstract: Primary malignant central nervous system (CNS) tumors only represent about 2% of all cancers. However, they are very often associated with high morbidity and mortality. Despite current standard-of-care therapy, such as surgery, irradiation, and chemotherapy, neither cure nor any toxic therapy against malignant CNS tumors has been developed so far. Nanotechnology may alter this situation. It offers a new promise for cancer diagnosis and treatment. This emerging technology, by developing and manufacturing materials using atomic and molecular elements, can provide a platform for the combination of diagnostics, therapeutics and delivery to the tumor, with subsequent monitoring of the response. This review focuses on recent developments in cancer nanotechnology with particular attention to nanoparticle systems, important tools for the improvement of drug delivery in brain tumor. The latest advances in both the research sector and in recent patents for cancer imaging and therapy are discussed.
Original languageEnglish
Pages (from-to)58-69
Number of pages12
JournalRecent Patents on Anti-Cancer Drug Discovery
Volume2011
DOIs
Publication statusPublished - 2011

Keywords

  • BRAIN
  • CANCER TREATMENT
  • DRUG DELIVERY
  • GENE THERAPY
  • NANOPARTICLE
  • NANOTECNOLOGY
  • PATENT
  • TUMOR

Fingerprint

Dive into the research topics of 'Nanotechnology advances in brain tumours: the state of the art'. Together they form a unique fingerprint.

Cite this